



Roche

FNSNF
FONDS NATIONAL SUISSE
SCHWEIZERISCHER NATIONALFONDS
FONDO NAZIONALE SVIZZERO
SWISS NATIONAL SCIENCE FOUNDATION

Enter protein #1: Submit Query

Frequent proteins

prot
- Act5C (8291)
- OMT1 (7971)
- RKG1 (7425)
- DI1 (7370)
- MP14 (7167)
- P53 (7107)
- RpII215 (7060)
- WWOX (6636)

3517467 results found in 611 ms Page 1 of 35175

prot: MDM2	prot: TP53	[collectionScore: 1126.030]
prot: ABL1	prot: BCR	[collectionScore: 772.855]
prot: BAX	prot: BCL2	[collectionScore: 588.988]
prot: BRCA1	prot: BRCA2	[collectionScore: 460.801]
prot: BCL2	prot: TP53	[collectionScore: 410.260]

Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression .

Abstract Methotrexate (MTX) exerts an anti-inflammatory effect via its metabolite adenosine , which activates adenosine receptors . The A3 adenosine receptor (A3AR) was found to be highly expressed in inflammatory tissues and peripheral blood mononuclear cells (PBMCs) of rats with adjuvant-induced arthritis (AIA) . CF101 (IB - MECA) , an A3AR agonist , was previously found to inhibit the clinical and pathological manifestations of AIA . The aim of the present study was to examine the effect of MTX on A3AR expression level and the efficacy of combined treatment with CF101 and MTX in AIA rats . AIA rats were treated with MTX , CF101 , or both agents combined . A3AR mRNA , protein expression and exhibition were tested in paw and PBMC extracts from AIA rats utilizing immunohistochemistry staining , RT - PCR and Western blot analysis . A3AR level was tested in PBMC extracts from patients chronically treated with MTX and healthy individuals . The effect of CF101 , MTX and combined treatment on A3AR expression level was also tested in PHA - stimulated PBMCs from healthy individuals and from MTX - treated patients with rheumatoid arthritis (RA) . Combined treatment with CF101 and MTX resulted in an additive anti-inflammatory effect in AIA rats . MTX induced A2AAR and A3AR over-expression in paw cells from treated animals . Moreover , increased A3AR expression level was detected in PBMCs from MTX - treated RA patients compared with cells from healthy individuals . MTX also increased the protein expression level of PHA - stimulated PBMCs from healthy individuals . The increase in A3AR level was counteracted in vitro by

4309 results found in 553 ms Page 1 of 44

Ribosomal protein S7 as a novel modulator of **p53** -**MDM2** interaction: binding to **MDM2** , stabilization of **p53** protein, and activation of **p53** function.(2007)

Herein, we demonstrate that S7 binds to **MDM2** , in vitro and in vivo, and that the interaction between **MDM2** and S7 leads to modulation of **MDM2** -**p53** binding by forming a ternary complex among **MDM2** , **p53** and S7.

The identification of S7 as a novel **MDM2** -interacting partner contributes to elucidation of the complex regulation of the **MDM2** -**p53** interaction and has implications in cancer prevention and therapy.

This results in the stabilization of **p53** protein through abrogation of **MDM2** -mediated **p53** ubiquitination.

pmid: 17310983 docScore:2.764 protPair: TP53:::MDM2

Cocompartmentalization of **p53** and **Mdm2** is a major determinant for **Mdm2** -mediated degradation of **p53** .(2001)

We find that (1) when proteasome activity is inhibited, ubiquitinated **p53** accumulates in the nucleus and not in the cytoplasm; (2) **Mdm2** with a mutated NES can efficiently mediate degradation of wild type **p53** or **p53** with a mutated NES; (3) the nuclear export inhibitor LMB can increase the steady-state level of **p53** by inhibiting **Mdm2** -mediated ubiquitination of **p53** ; and (4) LMB fails to inhibit **Mdm2** -mediated degradation of the p53NES mutant, demonstrating that **Mdm2** -dependent proteolysis of **p53** is feasible in the nucleus in the absence of any nuclear export.

The product of the **Mdm2** oncogene directly interacts with **p53** and promotes its ubiquitination and proteasomal degradation.

In this study we demonstrate that **Mdm2** can promote degradation of **p53** in the nucleus or in the cytoplasm, provided both proteins are colocalized.

pmid: 11597128 docScore:2.736 protPair: TP53:::MDM2